Clinical trials of neuroprotection for Parkinson's disease.
LeWitt
Peter A
PA
Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA. palewitt@ameritech.net
D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003401:Creatine / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D008995:Monoamine Oxidase / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010082:Oxepins / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010848:Picolinic Acids / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019782:Riluzole / Q000627:therapeutic use; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use; D014451:Ubiquinone / Q000627:therapeutic use
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D010082:Oxepins; D010848:Picolinic Acids; C111178:dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine; C031967:rasagiline; D014451:Ubiquinone; D012642:Selegiline; C059303:lazabemide; D019782:Riluzole; D008995:Monoamine Oxidase; D008911:Minocycline; D003401:Creatine